Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Atrovent

(Ipratropium bromide)

Phase 3Small molecule

Boehringer Ingelheim

Ipratropium bromide is used to treat breathing problems in people with chronic obstructive pulmonary disease (COPD) and asthma by relaxing the muscles around the airways to make breathing easier.[1] Atrovent is currently being investigated across 15 indications[3], with its most advanced program in Phase 3.[1]

Atrovent is one of 324 small molecule programs targeting Emphysema. It is currently in Phase 3.

15

Indications

24

Total Trials

1

Active Trials

323

Competitors

Pipeline

Status by Indication[3][1]

Indication

EmphysemaUnknown

Common ColdUnknown

Atopic EczemaUnknown

Familial DysautonomiaActive, not recruiting

Airway ObstructionUnknown

Respiratory InsufficiencyActive, not recruiting

Parkinson DiseaseActive, not recruiting

Chronic Obstructive Pulmonary DiseaseUnknown

Nasal CongestionUnknown

Chronic BronchitisUnknown

EmphysemaPreclinical

Unknown

Common ColdPreclinical

Unknown

Atopic EczemaPreclinical

Unknown

Familial DysautonomiaPhase 3

Active, not recruiting

Airway ObstructionPreclinical

Unknown

Respiratory InsufficiencyPhase 2

Active, not recruiting

Parkinson DiseasePhase 2

Active, not recruiting

Chronic Obstructive Pulmonary DiseasePreclinical

Unknown

Nasal CongestionPreclinical

Unknown

Chronic BronchitisPreclinical

Unknown

Showing 10 of 15 indications

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Atrovent

Boehringer Ingelheim

Veramyst

Xolair

Celexa

Symbicort

Decadron

QQuince Therapeutics S.p.A.

Tylenol

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

DUPIXENT

Blood Withdrawn

Emergent BioSolutions

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 2Not yet recruiting

Study completion

NCT07394036

Clinical

Trials by Indication[1]

Asthma5 trials

Budesonide Inhalation Suspension for Acute Asthma in Children

Completed·—·Phase 4·NCT00393367·179 enrolled

Nebulized Magnesium Sulfate as an Adjunct to Standard Therapy in Asthma Exacerbation

Unknown status·HHospital General Naval de Alta Especialidad - Escuela Medico Naval·Phase 4·NCT02584738·152 enrolled

Defining and Treating Depression-related Asthma

Completed·SState University of New York at Buffalo·Phase 1·NCT04617015·40 enrolled

Show 2 more trials

Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.

Completed·NNorthwell Health·Phase 3·NCT00588406·95 enrolled

Study to Assess the Efficacy of Ipratropium Bromide Associated With High Dose Salbutamol by Repeated Nebulisation Versus Repeat Nebulisation of Salbutamol Alone, in Acute Asthmatic Attacks in Young Children

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT02235428·3 enrolled

Chronic Obstructive Pulmonary Disease5 trials

Effects of Bronchodilators in Mild Chronic Obstructive Pulmonary Disease (COPD)

Completed·QQueen's University·Phase 4·NCT00202176·32 enrolled

Magnesium Sulfate Versus Ipratropuim Bromide in Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Completed·UUniversity of Monastir·Phase 3·NCT01136421·124 enrolled

Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02177253·1,118 enrolled

Show 2 more trials

Study to Assess the Effect of Salbutamol and Ipratropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients

Completed·UUniversity Hospital, Antwerp·Phase 4·NCT00911651·6 enrolled

Sensitivity of New Exercise Tests in Chronic Obstructive Pulmonary Disease (COPD)

Completed·LLaval University·N/A·NCT00807534·44 enrolled

Emergencies1 trial

Treating Respiratory Emergencies in Children Study

Completed·OOregon Health and Science University·Phase 2·NCT06074185·44 enrolled

Effectiveness1 trial

Effectiveness of Ipratropium Bromide in Preventing Exercise-induced Bronchoconstriction in Athletes

Completed·UUniversity of California, San Francisco·Phase 4·NCT01691079·20 enrolled

Respiratory insufficiency1 trial

Revefenacin in Acute Respiratory Insufficiency in COPD

Completed·UUniversity of California, Los Angeles·Phase 2·NCT04315558·21 enrolled

11 more indications

Familial dysautonomia1 trial

The Effects Of Bronchodilator Therapy On Respiratory And Autonomic Function In Patients With Familial Dysautonomia

Completed·NNYU Langone Health·Phase 3·NCT01987219·15 enrolled

Treatment1 trial

Ipratropium Bromide Spray as Treatment for Sialorrhea in Children

Unknown status·LLondon Health Sciences Centre·Phase 2·NCT03747536·30 enrolled

Airway obstruction1 trial

Role of Parasympathetic Activity in Mild to Severe Asthma With Fixed Airway Obstruction (PARASMA Study)

Unknown status·HHat Yai Medical Education Center·N/A·NCT05550402·60 enrolled

COPD1 trial

Ipratropium Bromide in Peri-Operative COPD

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT01943552·192 enrolled

Interstitial Lung Disease1 trial

Cryobiopsy Study to Assess Drug Distribution in Subjects With Suspected Interstitial Lung Disease

Completed· GSK logo

GSK··NCT03136120·8 enrolled

Exercise1 trial

Atrovent in Exercise Induced Laryngeal Obstruction (EILO)

Completed·HHaukeland University Hospital·Phase 1/2·NCT02755714·20 enrolled

Corticosteroids1 trial

Aridol Challenge as a Tool to Predict Treatment Response to Inhaled Corticosteroids in COPD

Completed·SSyntara·Phase 2·NCT00117182·140 enrolled

Drooling1 trial

Ipratropium Spray for Drooling Saliva in Parkinson's Disease

Completed·UUniversity Health Network, Toronto·Phase 2·NCT00296946·20 enrolled

ESS1 trial

Duration of Protective Effect From Inhaled Ipratropium Bromide on Methacholine Airway Hyperresponsiveness

Completed·UUniversity of Saskatchewan·Phase 4·NCT00605410·12 enrolled

Ventilation1 trial

Ventilation-drive Coupling to Evaluate The Efficacy of Inhaled Bronchodilators in Patients With COPD

Completed·ZZhujiang Hospital·N/A·NCT02296047·22 enrolled

Unspecified1 trial

Effect of Ipratropium Bromide on EILO

Not yet recruiting·CCook Children's Health Care System·Phase 2·NCT07394036·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 24 trial records for Ipratropium bromide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ipratropium bromide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ipratropium bromide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Muscarinic Acetylcholine Receptor M3 Antagonist[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Boehringer Ingelheim

Related News